Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible Fraud - Contact Levi & Korsinsky Today Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - February 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws.
What Happened?
On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
According to the Company's release, the FDA acknowledged the results of the previous GRACE and GRADIENT drug trials, but "concluded it could not arrive at a favorable benefit-risk assessment for relacordilant without Corcept providing additional evidence of effectiveness"
Why it Matters:
Today, in direct response to this news, Corcept's stock price fell by $31.42 (44.76%) per share to open at $38.78 per share on December 31, 2025.
This drop marks a new 52-week low for Corcept's stock, dropping to levels not seen since September 2024.
If you suffered a loss on your Corcept Therapeutics Incorporated securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282739
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible Fraud - Contact Levi & Korsinsky Today
2026-02-04 3:31 PM EST
Fraud Investigation: Levi & Korsinsky Investigates Ashford Hospitality Trust, Inc. (AHT) on Behalf of Shareholders
2026-02-03 2:53 PM EST
Shareholders Alert: Investigation Into Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky to Protect Your Rights
2026-02-02 12:26 AM EST
Dec 16, 2025
What makes a press release rise above the rest? We analyzed the most successful press releases of 2025 to see what caught attention and why. This year’s review looks at total views from human readers and AI systems across the top five hundred public company press releases distributed through TMX Newsfile in 2025. These views come from all of Newsfile’s general distribution channels, such as Yahoo and Apple. They reflect how audiences discovered and engaged with each announcement. Key Insights...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services